# EDGE-Gastric (NCT05329766)

> A Safety and Efficacy Study of Treatment Combinations With and Without Chemotherapy in Adult Participants With Advanced Upper Gastrointestinal Tract Malignancies

No report yet. It can be ordered.

- Drugs tested: domvanalimab plus zimberelimab; quemliclustat plus zimberelimab
- Indication: advanced gastric, gastroesophageal junction or esophageal cancer

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT05329766
- Phase: PHASE2
- Status: COMPLETED
- Sponsor: Arcus Biosciences, Inc.
- Conditions: Gastrointestinal Tract Malignancies
- Interventions: Domvanalimab; Quemliclustat; Zimberelimab; Fluorouracil; Leucovorin; Oxaliplatin
- Enrollment: 332
- Primary outcome: Number of Participants with Adverse Events (AEs)
- Primary outcome: Objective Response Rate (ORR) as measured by Response Evaluation Criteria in Solid Tumors (RECIST) v1.1

## Indexed commentary on EDGE-Gastric so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- X threads: 7
- YouTube: 4
- Podcasts: 1

## Order

Standard, $1,250 at most (a smaller delivered size costs its own price): https://www.erudio.com/contact?report=edge-gastric-nct05329766

## Free preview

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT05329766", "email": "<work email>"}; the inbox owner confirms by the emailed link.